Significant EU funding for international AICCELERATE consortium proposing a scalable AI tool for smart hospital
The AICCELERATE consortium consists of specialists in the fields of IT, machine learning, robotics, neurology, paediatrics and surgery from Finland, Italy, Spain, Turkey, Netherlands, Germany and Belgium.
Healthcare systems lack flexible AI solutions that allow hospitals to improve efficiency and the quality of patient care. Current solutions provide limited scalability and are confined to isolated applications. Scalable models that address data sharing, integration, privacy, and ethics are needed to ensure better adoption of AI in healthcare. Patient empowerment and evidence-based trust towards AI is a key part of the project. Evaluation activities will also focus on cost-benefit analysis of the AI-solutions.
AICCELERATE will develop partners’ existing digital solutions further to enable the development of a Smart Hospital Care Pathway (SHCP) Engine. This engine serves as a toolset for AI models and robotics to improve quality of care and health outcomes. It will also enable lean management and effective decision-making.
These tools are tested in three pilots that will provide feedback for improving the SHCP Engine: (i) patient flow management for ER and surgical units, (ii) digital care pathway for Parkinson’s disease, and (iii) paediatric service delivery.
The pilots are carried out by 5 hospital partners: Helsinki University Hospital and Oulu University Hospital from Finland, Ospedale Pediatrico Bambino Gesù from Italy, Barcelona Children's Hospital from Spain, and University Hospital Università degli Studi di Padova from Italy.
In addition to these above mentioned hospitals The AICCELERATE consortium is formed by Erasmus Univ. Rotterdam from Netherlands, RTO Fundació Eurecat from Spain, a Spanish non-profit TICBioMed, 6 SMEs aiming to advance the digitalization of the European healthcare services: Chino from Italy, Symptoma from Austria, Nuromedia from Germany, SRDC from Turkey, Evondos from Finland, NeuroPath from Belgium, and 2 large enterprises NEC Laboratories Europe from Germany and Innofactor from Finland. The preparation of the proposal was supported by Spinverse from Finland.
Keywords
Contacts
More information:
Development Manager Tuuli Pajunen
tuuli.pajunen@hus.fi, +358 40 182 5028
Research and Innovation Manager Suzan Ikävalko,
suzan.ikavalko@hus.fi, +358 50 583 4292
Images
About HUS
At HUS Helsinki University Hospital about 680 000 patients receive medical care annually. We have almost 27,000 professionals working for the best of all patients. We are responsible for providing specialized health care for the residents of our 24 member municipalities. In addition, the treatment of many rare and severe diseases is nationally centralized to HUS.
HUS is the biggest health care provider and the second largest employer in Finland. Our expertise is internationally recognized and accredited. As a university hospital, we continuously develop and evaluate our treatment methods and activities.
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Riktad screening kan förebygga farliga hjärnblödningar hos rökande medelålders kvinnor26.6.2025 08:58:18 EEST | Pressmeddelande
Enligt en undersökning utförd av finländska neurokirurger har till och med var tionde kvinna i åldern 50–60 år som röker ett hjärnaneurysm. En screening riktad till denna riskgrupp kan förebygga allvarliga hjärnblödningar.
Kohdennettu seulonta voi ehkäistä vaarallisia aivoverenvuotoja tupakoivilla keski-ikäisillä naisilla26.6.2025 08:58:18 EEST | Tiedote
Suomalaisten neurokirurgien tutkimuksen mukaan jopa joka kymmenennellä tupakoivalla 50–60-vuotiaalla naisella on aivovaltimopullistuma. Tälle riskiryhmälle kohdennettu seulonta voi ehkäistä vakavia aivoverenvuotoja.
Targeted screening may prevent dangerous cerebral hemorrhages in middle-aged women who smoke26.6.2025 08:58:18 EEST | Press release
According to a study by Finnish neurosurgeons, up to one in ten female smokers aged 50–60 have an intracranial aneurysm. Screening targeted at this risk group may prevent severe cerebral hemorrhages.
Arteriovenösa missbildningar i hjärnan orsakar sällan plötslig död utanför sjukhus24.6.2025 08:59:37 EEST | Pressmeddelande
En finländsk studie visar att arteriovenösa missbildningar i hjärnan (AVM) endast sällan leder till plötslig död utanför sjukhus. Överraskande nog visade sig epileptiska anfall vara en vanligare dödsorsak än hjärnblödningar.
Aivojen valtimo-laskimoepämuodostumat aiheuttavatkin vain harvoin äkkikuolemia sairaalan ulkopuolella24.6.2025 08:59:37 EEST | Tiedote
Suomalaistutkimus osoitti, että aivojen valtimo-laskimoepämuodostumat (AVM) johtavat vain harvoin äkillisiin kuolemiin sairaalan ulkopuolella. Yllättäen epilepsiakohtaukset osoittautuivat yleisemmäksi kuolinsyyksi kuin aivoverenvuodot.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom